Omeros

OMEROS CORP

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Movers_Stocks

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AFRM

INCY

KMDA

NEOG

OMER

TSLA

TYRA

USAR

Incyte, Tesla And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Stock Movers

ACON

DRCT

DTIL

INUV

KULR

LGCB

NAOV

PLAG

POLA

QUBT

REVB

Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

Analysts Pick 4 Stocks Poised for Growth, Including Tech Giants Microsoft And Meta

Initiation

Analyst Ratings

NATL

PONY

WKSP

This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Omeros Corp

Press Releases

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company's OMS527 Program to Treat Cocaine Use Disorder

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Arvinas

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Cormedix

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics

Evolus

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

GH Research

Harrow

Maze Therapeutics

Nuvation Bio

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Tilray Brands

Trevi Therapeutics

Xeris Biopharma Holdings, Inc. - Common Stock

Xeris Biopharma Holdings

Zevra Therapeutics

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

D. Boral Capital

Rodman & Renshaw

B of A Securities

Comments

Omeros

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga